The MUC1 mucin regulates the tumorigenic properties of human esophageal adenocarcinomatous cells

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1843, Issue 11, 2014, Pages 2432-2437

  Gronnier, Caroline ^a,b,c   Bruyère, Emilie ^a,b,c   Lahdaoui, Fatima ^a,b,c   Jonckheere, Nicolas ^a,b   Perrais, Michaël ^a,b   Leteurtre, Emmanuelle ^a,b,c   Piessen, Guillaume ^a,b,c   Mariette, Christophe ^a,b,c   Van Seuningen, Isabelle ^a,b  

^a JEAN PIERRE AUBERT RESEARCH CENTER   (France)

^b UNIV LILLE   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Adenocarcinoma; Esophagus; Invasion; MUC1; Mucin; Proliferation

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MINICHROMOSOME MAINTENANCE PROTEIN 6; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; MUCIN 1; PROTEIN KINASE B; SMALL INTERFERING RNA; TUMOR SUSCEPTIBILITY GENE 101 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER SIZE; CARCINOGENICITY; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL CANCER CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR INVASION; TUMOR XENOGRAFT;

EID: 84905229794     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2014.06.021     Document Type: Article

References (36)

1. Ferlay J., Parkin D.M., Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur. J. Cancer 2010, 46:765-781.
2. Luketich J.D., Pennathur A., Awais O., Levy R.M., Keeley S., Shende M., Christie N.A., Weksler B., Landreneau R.J., Abbas G., Schuchert M.J., Nason K.S. Outcomes after minimally invasive esophagectomy: review of over 1000 patients. Ann. Surg. 2012, 256:95-103.
3. Mariette C., Piessen G., Briez N., Gronnier C., Triboulet J.P. Oesophagogastric junction adenocarcinoma: which therapeutic approach?. Lancet Oncol. 2011, 12:296-305.
4. Mariette C., Piessen G., Triboulet J.P. Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities. Lancet Oncol. 2007, 8:545-553.
5. Fein M., Maroske J., Fuchs K.H. Importance of duodenogastric reflux in gastro-oesophageal reflux disease. Br. J. Surg. 2006, 93:1475-1482.
6. Kauer W.K., Peters J.H., DeMeester T.R., Feussner H., Ireland A.P., Stein H.J., Siewert R.J. Composition and concentration of bile acid reflux into the esophagus of patients with gastroesophageal reflux disease. Surgery 1997, 122:874-881.
7. Wild C.P., Hardie L.J. Reflux, Barrett's oesophagus and adenocarcinoma: burning questions. Nat. Rev. Cancer 2003, 3:676-684.
8. Colleypriest B.J., Ward S.G., Tosh D. How does inflammation cause Barrett's metaplasia?. Curr. Opin. Pharmacol. 2009, 9:721-726.
9. Prach A.T., MacDonald T.A., Hopwood D.A., Johnston D.A. Increasing incidence of Barrett's oesophagus: education, enthusiasm, or epidemiology?. Lancet 1997, 350:933.
10. Gronnier C., Bruyere E., Piessen G., Briez N., Bot J., Buob D., Leteurtre E., Van Seuningen I., Mariette C. Operatively induced chronic reflux in rats: a suitable model for studying esophageal carcinogenesis?. Surgery 2013, 154:955-967.
11. Jonckheere N., Van Seuningen I. The membrane-bound mucins: how large O-glycoproteins play key roles in epithelial cancers and hold promise as biological tools for gene-based and immunotherapies. Crit. Rev. Oncog. 2008, 14:177-196.
12. Jonckheere N., Van Seuningen I. The membrane-bound mucins: from cell signalling to transcriptional regulation and expression in epithelial cancers. Biochimie 2010, 92:1-11.
13. Mariette C., Piessen G., Leteurtre E., Hemon B., Triboulet J.P., Van Seuningen I. Activation of MUC1 mucin expression by bile acids in human esophageal adenocarcinomatous cells and tissues is mediated by the phosphatidylinositol 3-kinase. Surgery 2008, 143:58-71.
14. Bruyere E., Van Seuningen I. Mucins and Esophageal Carcinogenesis: New Biomarkers and/or Therapeutic Targets?. Advances in Medicine and Biology 2011, 23:145-157. Nova Science Publishers, Inc., Hauppage, NY. L.V. Berhardt (Ed.).
15. Piessen G., Wacrenier A., Briez N., Triboulet J.P., Van Seuningen I., Mariette C. Clinical impact of MUC1 and MUC4 expression in Barrett-associated oesophageal adenocarcinoma. J. Clin. Pathol. 2009, 62:1144-1146.
16. Hollingsworth M.A., Swanson B.J. Mucins in cancer: protection and control of the cell surface. Nat. Rev. Cancer 2004, 4:45-60.
17. Kufe D.W. Mucins in cancer: function, prognosis and therapy. Nat. Rev. Cancer 2009, 9:874-885.
18. Mariette C., Perrais M., Leteurtre E., Jonckheere N., Hemon B., Pigny P., Batra S., Aubert J.P., Triboulet J.P., Van Seuningen I. Transcriptional regulation of human mucin MUC4 by bile acids in oesophageal cancer cells is promoter-dependent and involves activation of the phosphatidylinositol 3-kinase signalling pathway. Biochem. J. 2004, 377:701-708.
19. Mukherjee P., Tinder T.L., Basu G.D., Gendler S.J. MUC1 (CD227) interacts with lck tyrosine kinase in Jurkat lymphoma cells and normal T cells. J. Leukoc. Biol. 2005, 77:90-99.
20. Piessen G., Jonckheere N., Vincent A., Hemon B., Ducourouble M.P., Copin M.C., Mariette C., Van Seuningen I. Regulation of the human mucin MUC4 by taurodeoxycholic and taurochenodeoxycholic bile acids in oesophageal cancer cells is mediated by hepatocyte nuclear factor 1alpha. Biochem. J. 2007, 402:81-91.
21. van der Sluis M., Melis M.H., Jonckheere N., Ducourouble M.P., Buller H.A., Renes I., Einerhand A.W., Van Seuningen I. The murine Muc2 mucin gene is transcriptionally regulated by the zinc-finger GATA-4 transcription factor in intestinal cells. Biochem. Biophys. Res. Commun. 2004, 325:952-960.
22. Ye Q., Yan Z., Liao X., Li Y., Yang J., Sun J., Kawano T., Wang X., Cao Z., Wang Z., Huang L. MUC1 induces metastasis in esophageal squamous cell carcinoma by upregulating matrix metalloproteinase 13. Lab. Invest. 2011, 91:778-787.
23. Etoh T., Inoue H., Yoshikawa Y., Barnard G.F., Kitano S., Mori M. Increased expression of collagenase-3 (MMP-13) and MT1-MMP in oesophageal cancer is related to cancer aggressiveness. Gut 2000, 47:50-56.
24. Satoh S., Hinoda Y., Hayashi T., Burdick M.D., Imai K., Hollingsworth M.A. Enhancement of metastatic properties of pancreatic cancer cells by MUC1 gene encoding an anti-adhesion molecule. Int. J. Cancer 2000, 88:507-518.
25. van de Wiel-van Kemenade E., Ligtenberg M.J., de Boer A.J., Buijs F., Vos H.L., Melief C.J., Hilkens J., Figdor C.G. Episialin (MUC1) inhibits cytotoxic lymphocyte-target cell interaction. J. Immunol. 1993, 151:767-776.
26. Ren J., Li Y., Kufe D. Protein kinase C delta regulates function of the DF3/MUC1 carcinoma antigen in beta-catenin signaling. J. Biol. Chem. 2002, 277:17616-17622.
27. Carraway K.L., Ramsauer V.P., Haq B., Carothers Carraway C.A. Cell signaling through membrane mucins. Bioessays 2003, 25:66-71.
28. Liu D.C., Yang Z.L., Jiang S. Identification of PEG10 and TSG101 as carcinogenesis, progression, and poor-prognosis related biomarkers for gallbladder adenocarcinoma. Pathol. Oncol. Res. 2011, 17:859-866.
29. Carstens M.J., Krempler A., Triplett A.A., Van Lohuizen M., Wagner K.U. Cell cycle arrest and cell death are controlled by p53-dependent and p53-independent mechanisms in Tsg101-deficient cells. J. Biol. Chem. 2004, 279:35984-35994.
30. Frisa P.S., Jacobberger J.W. Cytometry of chromatin bound Mcm6 and PCNA identifies two states in G1 that are separated functionally by the G1 restriction point. BMC Cell. Biol. 2010, 11:26.
31. Chen Q., Li D., Ren J., Li C., Xiao Z.X. MUC1 activates JNK1 and inhibits apoptosis under genotoxic stress. Biochem. Biophys. Res. Commun. 2013, 440:179-183.
32. Paterson A.L., Shannon N.B., Lao-Sirieix P., Ong C.A., Peters C.J., O'Donovan M., Fitzgerald R.C. A systematic approach to therapeutic target selection in oesophago-gastric cancer. Gut 2013, 62:1415-1424.
33. Abdel-Latif M.M., Kelleher D., Reynolds J.V. Potential role of NF-kappaB in esophageal adenocarcinoma: as an emerging molecular target. J. Surg. Res. 2009, 153:172-180.
34. Ren J., Agata N., Chen D., Li Y., Yu W.H., Huang L., Raina D., Chen W., Kharbanda S., Kufe D. Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents. Cancer Cell 2004, 5:163-175.
35. Ahmad R., Alam M., Rajabi H., Kufe D. The MUC1-C oncoprotein binds to the BH3 domain of the pro-apoptotic BAX protein and blocks BAX function. J. Biol. Chem. 2012, 287:20866-20875.
36. Raina D., Ahmad R., Kumar S., Ren J., Yoshida K., Kharbanda S., Kufe D. MUC1 oncoprotein blocks nuclear targeting of c-Abl in the apoptotic response to DNA damage. EMBO J. 2006, 25:3774-3783.